HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 290/3/G519    most recent 00113.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Kanda, N. Articles by Chiba, T. Search for Related Content PubMed PubMed Citation Articles by Kanda, N. Articles by Chiba, T.

MUCOSAL BIOLOGY

Involvement of cyclooxygenase-2 in gastric mucosal hypertrophy in gastrin transgenic mice

¹Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto; and ²Department of Molecular Medicine, Institute of Molecular and Cellular Regulation, Gunma University, Maebashi, Japan

Submitted 15 March 2005 ; accepted in final form 26 October 2005

Gastrin promotes gastric mucosal growth, and hypergastrinemia induces gastric mucosal hypertrophy. Recently, it has been reported that gastrin induces cyclooxygenase-2 (COX-2) in human gastric and colorectal cancer cell lines. However, whether COX-2 is involved in gastrin-induced gastric mucosal growth in vivo is unknown. We investigated the role of COX-2 in gastrin-induced gastric mucosal hypertrophy using gastrin transgenic mice. Hypergastrinemic mice [mice with mutated gastrin under the control of the -actin promoter (ACT-GAS mice)] received the COX-2 inhibitor celecoxib (0, 200, or 500 mg/kg of diet) from 5 wk of age and were killed at 16 or 24 wk. Some ACT-GAS mice received celecoxib from 16 wk and were killed at 24 wk. Eighty-week-old ACT-GAS mice without celecoxib treatment were also examined. The thickness of the gastric mucosa, cell populations, COX-2 expression, and PGE₂ levels were evaluated. All ACT-GAS mice showed gastric mucosal hypertrophy, and four of six 80-wk-old ACT-GAS mice developed gastric cancer. COX-2 was expressed in interstitial cells of the hypertrophic gastric mucosa and gastric cancers. Moreover, PGE₂ levels in the gastric mucosa of ACT-GAS mice were significantly higher than those of normal mice. With treatment with celecoxib, PGE₂ levels, the gastric mucosal thickness, and the number of total gastric cells per gastric gland of ACT-GAS mice were significantly decreased. The decrease in gastric mucosal thickness was caused by a reduction of foveolar hyperplasia. The thickness of glandules and the number of Ki67-positive cells were not significantly changed. In conclusion, COX-2 contributes to gastrin-induced mucosal hypertrophy of the stomach.

prostaglandin E₂; gastric cancer; foveolar hyperplasia

This article has been cited by other articles:

				S. Tu, A. L. Chi, S. Lim, G. Cui, Z. Dubeykovskaya, W. Ai, J. V. Fleming, S. Takaishi, and T. C. Wang Gastrin regulates the TFF2 promoter through gastrin-responsive cis-acting elements and multiple signaling pathways Am J Physiol Gastrointest Liver Physiol, June 1, 2007; 292(6): G1726 - G1737. [Abstract] [Full Text] [PDF]